A Blood Test Receives FDA Approval for Early Colorectal Cancer Detection for the First Time

A new era is beginning for millions who delay screening because of the fear or inconvenience of colonoscopy. As of 29 July, the FDA approved the Shield blood test. Colon cancer risk can now be screened through a routine blood draw.

The First Concrete Step in Liquid Biopsy Screening

On 29 July, the FDA approved a blood test developed by Guardant Health for average-risk adults aged 45 and over: Shield This blood test received the following status through the decision:

• Became, as an FDA-approved primary screening option, the first blood test. This was its new status.
• Became covered by Medicare (US government insurance).
• Joined noninvasive screening methods, such as stool tests.

Although Shield is highly successful in detecting cancer (83%), its detection rate for precancerous lesions, advanced adenomas (polyps), is approximately 13%. Therefore, when the test is positive or a high-risk situation exists, colonoscopy remains the gold standard and is needed to detect/remove polyps. The blood test is an excellent “first step” for reaching people who do not undergo screening at all.

DROZDOĞAN Academy Commentary

The best screening test is the one “the patient actually takes.” However excellent colonoscopy may be, it provides no benefit if people do not undergo it. The FDA’s Shield approval offers an accessible, scientifically supported solution beyond “better than nothing.” Wider adoption could be our strongest opportunity to detect cancer at a treatable early stage rather than an advanced one.